Get the Stockscreener App
59.34
7.22%
-4.615
After Hours:
58.76
-0.585
-0.99%
Moderna Inc stock is traded at $59.34, with a volume of 8.32M.
It is down -7.22% in the last 24 hours and up +26.59% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$63.96
Open:
$64.07
24h Volume:
8.32M
Relative Volume:
1.20
Market Cap:
$23.55B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-7.285
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
+13.84%
1M Performance:
+26.59%
6M Performance:
+70.04%
1Y Performance:
+129.13%
1-Day Range:
$57.50
$65.51
1-Week Range:
$51.66
$67.74
52-Week Range:
$22.28
$67.74
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
59.34 | 25.38B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
466.79 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.50 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
903.75 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.41 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
165.81 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Should You Buy Moderna Before Aug. 5? - The Globe and Mail
Should You Buy Moderna Before Aug. 5? - The Motley Fool
Moderna, Inc.’s stock price dips to $59.34, marking a 7.22% downturn: Is it time to buy? - Smartkarma
Gov't Says It Should Face Vax IP Claims, Not Moderna - Law360
Moderna Stock’s 6-Day Rally Ends in a Dive. Why It’s One of the S&P 500’s Biggest Losers Today. - Barron's
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus
Moderna’s mRNA flu vaccine passes FDA AdCom, review underway - Yahoo Finance
Leerink Partners Adjusts Price Target on Moderna to $24 From $21, Maintains Underperform Rating - marketscreener.com
Moderna Stock On Fire: Up 39% With 6-Day Winning Streak - Trefis
Moderna Stock 6-Day Winning Spree: Stock Climbs 39% - Trefis
FDA Panel Backs Moderna’s mRNA-Based Influenza Vaccine for Adults 50+ - Medical Professionals Reference
Moderna (MRNA) Receives Unanimous FDA Panel Support for Flu Vacc - GuruFocus
MRNA Stock Quote Price and Forecast - CNN
Moderna Has Some Key Approvals Ahead. Is the Stock a Buy? - AOL.com
Virtu Financial LLC Takes $2.42 Million Position in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Shares Sold by Tobam - MarketBeat
FDA panel backs first-of-its-kind flu vaccine using mRNA technology - Los Angeles Times
FDA AdCom unanimously backs Moderna’s mFlusiva - The Pharma Letter
mRNA Patent Wars Update: Delaware Court Allows Moderna and Pfizer/BioNTech to Assert Laches in GSK Patent Infringement Cases - JD Supra
FDA panel supports first mRNA-based flu vaccine - National News Desk
FDA Advisory Panel Votes 9-0 in Favor of Moderna's mRNA Flu Vaccine, Setting Stage for August Decision - BioPharm International
FDA Panel Unanimously Backs Moderna mRNA Flu Vaccine: Full Approval Expected by August - Tech Times
Moderna's Flu Vaccine Clears Key FDA Panel Vote As Advisory Committee Backs Shot 9-0 - Benzinga
MRNA Up as Influenza Vaccine Wins Unanimous FDA Advisory Panel Backing - Yahoo Finance
US FDA Panel Recommends First-Ever mRNA Flu Shot For Older Adults: All About The Moderna Vaccine - Health and Me
Moderna’s mRNA flu shot wins unanimous support at FDA adcomm in rebuke of former leadership - BioSpace
Hamilton Wealth LLC Acquires New Stake in Moderna, Inc. $MRNA - MarketBeat
Moderna flu vaccine OK’d by FDA panel - The Arkansas Democrat-Gazette
Moderna Stock On Fire: Up 34% With 5-Day Winning Streak - Trefis
First-of-its-kind flu shot may be approved for older adults - NewsNation
FDA panel gives nod to Moderna flu shot - The Hill
Moderna seeks FDA approval for its new flu shots that us MRNA technology - CBS News
FDA panel recommends mRNA flu vaccine for older adults - The Hill
Moderna (MRNA) Receives Unanimous Support for Seasonal Flu Vacci - GuruFocus
MRNA Stock Clocks Best Week In Over 4 Years On FDA Advisory Committee Endorsement For Flu Vaccine - TradingView
🔎 Under the Radar: Moderna Stock Rises on Flu-Shot Recommendation - WSJ
Moderna gains unanimous FDA panel endorsement of flu vaccine - Seeking Alpha
FDA panel backs Moderna’s flu vaccine for older adults - Investing.com
Doctor explains Moderna's candidate for first MRNA flu shot - WCVB
Moderna options trading surges to 121,257 contracts today By Investing.com - Investing.com Nigeria
Moderna (MRNA) Receives Positive Advisory Committee Vote for Inf - GuruFocus
Moderna (MRNA) Receives Positive FDA Advisory Votes for Flu Vacc - GuruFocus
FDA panel recommends Moderna’s mRNA flu shot for older adults - AOL.com
Moderna (MRNA) Shares Rise Following FDA Advisory Committee Appr - GuruFocus
Moderna flu vaccine wins unanimous support from FDA panel - BioPharma Dive
Moderna’s mRNA Flu Vaccine Wins FDA Advisory Committee Backing - Bloomberg.com
FDA Votes in Favor of Benefit-Risk Profile for Moderna’s Flu Vaccine - WSJ
FDA panel backs Moderna’s flu vaccine for older adults By Investing.com - Investing.com Canada
FDA advisers back Moderna's flu vaccine for older adults, 9-0 - Stock Titan
Moderna Secures Favorable FDA Panel Recommendation for mRNA Flu Vaccine - marketscreener.com
Stock Traders Buy High Volume of Moderna Call Options (NASDAQ:MRNA) - MarketBeat
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.15%
0.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):